Afterwards, they also provided evidences that disruption of N-linked glycosylation could reduce RTK signaling in vivo and increase radiosensitivity of gliomas, suggesting that targeting N-linked glycosylation may combine favorably with other classes of EGFR inhibitors to reduce both oncogenic signaling and the mechanisms of therapeutic resistance [16]. Here, EGFR is linked to glioma.